Dana-Farber backed Neomorph hunts 'undruggable' proteins with new round of investor cash for hires, development
Big investments in protein degradation, the process of unlocking previously “undruggable” binding sites for novel therapeutics, are nothing new with some of pharma’s biggest players already dabbling in the field. But a new biotech backed by the Dana-Farber Cancer Institute believes its “molecular glue” platform could help it stand out — and it’s got the funding to test its hypothesis.
Neomorph, a biotech specializing in the buzzy field of protein degradation, has snared a $105 million Series A financing round to scale up its R&D team and hunt for new medicines in a range of therapeutic areas, particularly oncology, the company said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.